{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T16:10:04Z","timestamp":1738858204253,"version":"3.37.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"544","license":[{"start":{"date-parts":[[1971,2,1]],"date-time":"1971-02-01T00:00:00Z","timestamp":34214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1971,2,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>L-Dopa and amantadine hydrochloride were separately given to patients with diverse extra-pyramidal disorders including progressive supranuclear palsy; porto-systemic encephalopathy; oculogyric crises; drug-induced Parkinsonism; Huntington\u2019s chorea, hemiballismus; spasmodic torticollis, familial tremor; and athetosis. Akinesia and rigidity were improved in the first two conditions and simultaneously there was improvement in disordered eye movement. Amantadine provoked an exacerbation in spasmodic torticollis and familial tremor. No other condition was influenced. Both amantadine and L-dopa will facilitate eye movement mechanisms: it seems probable that both drugs act on dopamine-sensitive areas within the CNS. Neither drug will give significant benefit in the above disorders.<\/jats:p>","DOI":"10.1136\/pgmj.47.544.116","type":"journal-article","created":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T20:27:15Z","timestamp":1230582435000},"page":"116-119","source":"Crossref","is-referenced-by-count":9,"title":["L-Dopa and amantadine hydrochloride in extra-pyramidal disorders"],"prefix":"10.1093","volume":"47","author":[{"given":"J D","family":"Parkes","sequence":"first","affiliation":[{"name":"Department of Neurology, King\u2019s College Hospital , London, S.E.5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R P","family":"Knill-Jones","sequence":"additional","affiliation":[{"name":"Department of Neurology, King\u2019s College Hospital , London, S.E.5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P J","family":"Clements","sequence":"additional","affiliation":[{"name":"Department of Neurology, King\u2019s College Hospital , London, S.E.5"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1971,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(69)90662-X","article-title":"L-Dopa and juvenile Huntington's disease","volume":"ii,","author":"BARBEAU, A.","year":"1969","unstructured":"BARBEAU, A. (1969) L-Dopa and juvenile Huntington's disease. Lancet, ii, 1066.","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0140-6736(70)91259-6","article-title":"Treatment of Wilson's disease with L-dopa after failure with penicillamine","volume":"i,","author":"BARBEAU, A.; FRIESEN, H.","year":"1970","unstructured":"BARBEAU, A. & FRIESEN, H. (1970) Treatment of Wilson's disease with L-dopa after failure with penicillamine. Lancet, i, 1180.","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/brain\/92.3.663","article-title":"Progressive supranuclear palsy. Clinico-pathological study of four cases","volume":"92","author":"BEHRMAN, S.; CARROLL, J.D.; JANOTA, I.; MATTHEWS, W.B.","year":"1969","unstructured":"BEHRMAN, S., CARROLL, J.D., JANOTA, I. & MATTHEWS, W.B. (1969) Progressive supranuclear palsy. Clinico-pathological study of four cases. Brain, 92, 663.","journal-title":"Brain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0031-6997(25)07430-7","article-title":"Interaction of drugs with norepinephine in the brain","volume":"11","author":"BRODIE, B.B.; SPECTOR, S.; SHORE, P.A.","year":"1959","unstructured":"BRODIE, B.B., SPECTOR, S. & SHORE, P.A. (1959) Interaction of drugs with norepinephine in the brain. Pharmacological Reviews, 11, 548.","journal-title":"Pharmacological Reviews"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism-chronic treatment with L-dopa","volume":"280","author":"COTZIAS, G.C.; PAPAVASILIOU, P.S.; GELLENE, R.","year":"1969","unstructured":"COTZIAS, G.C., PAPAVASILIOU, P.S. & GELLENE, R. (1969) Modification of Parkinsonism-chronic treatment with L-dopa. New England Journal of Medicine, 280, 337.","journal-title":"New England Journal of Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1126\/science.169.3941.203","article-title":"Amantadine-dopamine interaction","volume":"169","author":"GRELAK, R.P.; CLARK, R.; STUMP, J.M.; VERNIER, V.G.","year":"1970","unstructured":"GRELAK, R.P., CLARK, R., STUMP, J.M. & VERNIER, V.G. (1970) Amantadine-dopamine interaction. Science, 169, 203.","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0031-6997(25)07154-6","article-title":"Dopamine (3-hydroxytyramine) and brain function","volume":"18","author":"HORNYKIEWICZ, 0","year":"1966","unstructured":"HORNYKIEWICZ, 0. (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacological Reviews, 18, 925.","journal-title":"Pharmacological Reviews"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.1961.03040360001001","article-title":"Drug-induced extrapyramidal reactions","volume":"177","author":"MCGEER, P.L.; BOULDING, J.E.; GIBSON, W.C.; FOULKES, R.G.","year":"1961","unstructured":"MCGEER, P.L., BOULDING, J.E., GIBSON, W.C. & FOULKES, R.G. (1961) Drug-induced extrapyramidal reactions. Journal of the American Medical Association, 177, 665.","journal-title":"Journal of the American Medical Association"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197001012820102","article-title":"Chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane","volume":"282","author":"MENA, I.; COURT, J.; FUENZALIDA, S.; PAPAVASILIOU, P.S.; COTZIAS, G.C.","year":"1970","unstructured":"MENA, I., COURT, J., FUENZALIDA, S., PAPAVASILIOU, P.S. & COTZIAS, G.C. (1970) Chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. New England Journal of Medicine, 282, 5.","journal-title":"New England Journal of Medicine"},{"key":"ref_10","article-title":"Modification by L-dopa of a case of progressive supranuclear palsy","volume":"593","author":"MENDELL, J.R.; CHASE, T.N.; ENGEL, W.K.","year":"1970","unstructured":"MENDELL, J.R., CHASE, T.N. & ENGEL, W.K. (1970) Modification by L-dopa of a case of progressive supranuclear palsy. Lancet, i, 593.","journal-title":"Lancet"},{"key":"ref_11","article-title":"Comparative trial of L-dopa and amantadine hydrochloride in the treatment of Parkinsonism. International JournalofExperimentalPharmacology and Therapeutics","author":"PARKES, J.D.; ZILKHA, K.J.; KNILL-JONES, R.P.; CLEMENTS, P.J.; BAXTER, R.","year":"1970","unstructured":"PARKES, J.D., ZILKHA, K.J., KNILL-JONES, R.P., CLEMENTS, P.J. & BAXTER, R. (1970). Comparative trial of L-dopa and amantadine hydrochloride in the treatment of Parkinsonism. International JournalofExperimentalPharmacology and Therapeutics. (In press.)"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0041-008X(69)90066-0","article-title":"The toxicologic and pharmacologic properties of amantadine hydrochloride","volume":"15","author":"VERNIER, V.G.; HARMON, J.B.; STUMP, J.M.; LYNES, T.E.; MARVEL, J.P.; SMITH, D.H.","year":"1969","unstructured":"VERNIER, V.G., HARMON, J.B., STUMP, J.M., LYNES, T.E., MARVEL, J.P. & SMITH, D.H. (1969) The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicology and Applied Pharmacology, 15, 642.","journal-title":"Toxicology and Applied Pharmacology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-196509000-00001","article-title":"The acquired (non-Wilsonian) type of chronic heptatocerebral degeneration","volume":"44","author":"VICTOR, M.; ADAMS, R.D.; COLE, M.","year":"1965","unstructured":"VICTOR, M., ADAMS, R.D. & COLE, M. (1965) The acquired (non-Wilsonian) type of chronic heptatocerebral degeneration. Medicine (Baltimore), 44, 345.","journal-title":"Medicine (Baltimore)"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/47\/544\/116\/49298720\/postgradmedj-47-116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/47\/544\/116\/49298720\/postgradmedj-47-116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T15:35:16Z","timestamp":1738856116000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/47\/544\/116\/7051273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1971,2,1]]},"references-count":13,"journal-issue":{"issue":"544","published-online":{"date-parts":[[1971,2,1]]},"published-print":{"date-parts":[[1971,2,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.47.544.116","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"type":"print","value":"0032-5473"},{"type":"electronic","value":"1469-0756"}],"subject":[],"published-other":{"date-parts":[[1971,2]]},"published":{"date-parts":[[1971,2,1]]}}}